Kurzfassung

A phase III, randomized, double-blind, Placebo-controled Clinical Trial to
Evaluate the efficacy and safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo +
Trastuzumab + Docetaxel in previously untreated HER2- Positive metastatic breast cancer